Current Clinical Trials

  • DEP® docetaxel – Phase 2

  • DEP® cabazitaxel – Phase 1 / 2

DEP® docetaxel – Phase 2

Status: Recruiting patients

  • Open-label, two-stage design
  • Objectives are to establish anti-tumour activity (efficacy) and safety of DEP® docetaxel (at the Recommended Phase 2 Dose (RP2D) of 60mg/m2)
  • First stage to enrol ~20 patients with either lung or prostate cancer (the key approved indications for standard docetaxel (e.g. Taxotere®))
  • Second stage to enrol a further 20 patients (tumour types based on results from the first stage)
  • Also investigating the potential benefits of combining DEP® docetaxel with another anti-cancer agent, nintedanib (Vargatef®)

Download: DEP docetaxel positive phase 1 results; phase 2 commences  (pdf, 363kb)


DEP® cabazitaxel - Phase 1 / 2

Status: Recruiting patients

  • Open-label, two-part study (Phase 1 sequential dose escalation, phase 2 dose expansion)
  • Objectives are to define the maximum tolerated dose (MTD) to establish safety and explore anti-tumour activity (efficacy) of DEP® cabazitaxel
  • Planning to enrol approximately 35 patients across the phase 1 / 2 trial, with the trial being conducted at multiple sites including Guy’s Hospital London and University College London Hospital

Download: Starpharma to commence DEP cabazitaxel phase 1 / 2 trial (pdf, 147kb)










For more information regarding trial participation email:




Learn more about clinical trials

© Starpharma Holdings Limited 2017